Follow Us

Menu
Log in


Log in


Agenda

2026 IAP Fall CME Meeting 

IAP MEMBERS MUST LOG IN FOR REGISTRATION DISCOUNT

IAP 2026 Fall CME Meeting (virtual)

Meeting Points

 Register Now     Faculty Biosketches   Agenda     CME Information   2026_Fall_CME_Meeting_Brochure.pdf

 

John Oyelakin-Ogunbileje, PhD

Assistant Professor of Clinical Pathology & Laboratory Medicine

Medical Director at Simon Cancer Center Laboratory at University Hospital, Indianapolis, IN

Medical Director, Sweat Chloride Testing at Riley Hospital for Children, Indianapolis, IN

   

Rohit Gulati, MBBS

Associate Professor of Clinical Pathology & Laboratory Medicine

Director, Hematopathology Fellowship Program

Carrie L. Phillips, MD

Bicentennial Professor of Pathology & Laboratory Medicine

Professor of Medicine

Vice Chair Faculty and Staff Development

Hannah Hyaduck, MD

Chief Resident, IU Pathology Residency Program


Lin Wang, MD, PhD

Assistant Research Professor of Pathology & Laboratory Medicine

Indiana University School of Medicine



Breaking Diagnostic Silos in Multiple Myeloma (Part 1)

Objectives:

At the end of this activity, participants should be able to:  

  • Interpret complex and discordant laboratory findings while recognizing analytical pitfalls across sFLC, electrophoresis, and MASS-FIX workflows 
  • Identify diagnostic pearls and avoid interferences such as therapeutic monoclonal antibodies and CKD-related result variability
  • Recognize assay limitations, including antigen excess, non-harmonized reagents, and paraprotein interference.

  • What's it about?

Multiple myeloma is a genetically heterogeneous plasma cell neoplasm with manifestations across bone, kidney, and the hematopoietic system. Diagnosis depends on tests owned by different laboratory specialties — serum free light chains, protein electrophoresis, and mass spectrometry–based monoclonal protein testing in clinical chemistry; marrow morphology, flow cytometry, and clonality in hematopathology; and biopsy interpretation in renal pathology. In practice these are run and reported as linear, compartmentalized workflows. Discordant results are not reconciled across specialties, so diagnostic delays and misinterpretations persist, and minimal residual disease (MRD) assessment is inconsistently integrated with hematologic and renal findings.

Breaking Diagnostic Silos in Multiple Myeloma (Part 2)

Objectives:

At the end of this activity participants should be able to:

  •  Differentiate myeloma-related renal lesions using clinicopathologic correlation with recent RPS/IKMG consensus criteria.
  •  Apply an algorithmic, multidisciplinary approach integrating biochemical, hematologic, renal, and radiological data in multiple myeloma diagnosis and MRD evaluation.
  •  Align biopsy patterns with hematologic clonality and clinical risk stratification per IMWG, NCCN, and WHO guidelines



Molecular Genetic Pathology in Multiple Myeloma

Objectives:

At the end of this activity participants should be able to:

  • Review the current standard for molecular/cytogenetic testing in multiple myeloma (MM). 
  •  Recognize what next-generation sequencing (NGS) can add to the diagnosis and prognostic assessment of multiple myeloma. 
  •  Explain the role and importance of plasma-cell enrichment in molecular testing of MM and describe e a practical approach for the validation of an NGS assay in MM.

What's it about?

Molecular testing also requires coordinated specimen preparation and interpretation. Multiple myeloma is a genetically heterogeneous plasma-cell neoplasm and molecular and cytogenetic testing is important for diagnosis, classification, and risk assessment. This presentation will provide information for participants to understand current testing methods, the additional information provided by NGS, and the importance of plasma-cell enrichment for accurate testing. This presentation will review these topics and share the Indiana University experience with NGS validation in multiple myeloma.




    Agenda

    Morning Session

    9:00 am

    Breaking Diagnostic Silos in Multiple Myeloma (Part 1)

    10:00 am 

    Breaking Diagnostic Silos in Multiple Myeloma (Part 2)


    11:00 am Break

    11:15 am Molecular Testing in Multiple Myeloma: Current and Future Perspectives


    12:15 pm Follow-up Q and A

    12:30 pm End of Program











    CME information

    Joint Providership Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the College of American Pathologists and the Indiana Association of Pathologists.. The College of American Pathologists is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation Statement

    The College of American Pathologists designates this live (or internet live) educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Disclaimer

    The content of this accredited CE (CME) activity does not necessarily reflect the view or policies of the College of American Pathologists.

    Disclosure Information

    Below you will find the financial disclosure relationships for anyone who was able to affect the content of this educational activity. 

    The following speakers/planners have no financial relationships to disclose:

    Andrew Tharp, MD

    Sheila Segura, MD

    Carrie Phillips, MD

    Norma Erickson, MA

    Lin Wang, MD, PhD

    Rohit Gulati, MBBS

    Hannah Hyaduck, MD


    No speakers/planners disclosed financial relationships.

    The following In-Kind Support has been received for this activity:

    None

    The following Commercial Support has been received for this activity:

    None


    Faculty Bios

    John Oyelakin-Ogunbileje, PhD


    Assistant Professor of Clinical Pathology & Laboratory Medicine

    Medical Director at Simon Cancer Center Laboratory at University Hospital, Indianapolis, IN

    Medical Director, Sweat Chloride Testing at Riley Hospital for Children, Indianapolis, IN

    Rohit Gulati, MD

    Director, Hematopathology

    Associate Professor of Clinical Pathology & Laboratory Medicine

    Director, Hematopathology Fellowship Program


    Carrie L. Phillips, MD

    Bicentennial Professor of Pathology & Laboratory Medicine

    Professor of Medicine

    Vice Chair Faculty and Staff Development

    Lin Wang, MD, PhD

    Dr. Lin Wang is an Assistant Research Professor in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine. She received her MD in Pediatrics from Inner Mongolia Medical College and her PhD in Cell Biology from Peking Union Medical College. She completed her postdoctoral fellowship at the Herman B Wells Center for Pediatric Research at Indiana University School of Medicine before joining the Department of Pathology and Laboratory Medicine. Dr. Wang’s research focuses on assay development, clinical validation, and the integration of emerging technologies into routine clinical diagnostics. Her work bridges innovative laboratory methods and technologies with clinical practice to address the evolving needs of clinical laboratories and, ultimately, improve patient care.




    Return to Top

    Register now




    Powered by Wild Apricot Membership Software